Lexaria Bioscience (LEXX) Operating Expenses (2017 - 2026)

Lexaria Bioscience has disclosed Operating Expenses across 10 years of filings, most recently posting $1.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $1.5 million, down 49.68% year-over-year; the trailing twelve-month figure through Feb 2026 was $9.8 million (down 0.79% YoY), and the FY2025 annual result was $12.6 million, up 102.56% from the prior year.
• Operating Expenses came in at $1.5 million for Q1 2026 at Lexaria Bioscience, down from $1.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $3.9 million in Q2 2025 to a low of $813005.0 in Q1 2024.
• The 5-year median for Operating Expenses is $1.8 million (2022), against an average of $2.0 million.
• Across the five-year window, Operating Expenses jumped 259.78% in 2025 and tumbled 49.68% in 2026, its largest moves.
• Lexaria Bioscience's Operating Expenses stood at $1.8 million in 2022, then fell by 27.67% to $1.3 million in 2023, then surged by 123.39% to $2.9 million in 2024, then slumped by 45.21% to $1.6 million in 2025, then slipped by 6.46% to $1.5 million in 2026.
• The last three Operating Expenses figures came in at $1.5 million (Q1 2026), $1.6 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.